Study summary

Rituximab and cyclophosphamide with steroids worked about equally well

Rituximab vs cyclophosphamide meta-analysis · 11 studies, 1,068 people · Published March 2026, BMC Nephrology

0.85risk ratio for remission at 12 months (not significant)

What was tested

A pooled analysis of randomized and cohort studies comparing rituximab with cyclophosphamide plus steroids for moderate- or high-risk primary membranous nephropathy.

What they found

What it means

Both remain standard options; rituximab is often preferred because it avoids cyclophosphamide toxicity.

BMC Nephrol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.